Objective: To investigate the characteristics of and risk factors for mortality among non-HIV-infected immunocompromised patients with an in-hospital diagnosis of tuberculosis.

Methods: This was a two-year, retrospective cohort study of patients with an in-hospital diagnosis of tuberculosis. The predictive factors for mortality were evaluated.

Results: During the study period, 337 hospitalized patients were diagnosed with tuberculosis, and 61 of those patients presented with immunosuppression that was unrelated to HIV infection. Extrapulmonary tuberculosis was found in 47.5% of cases. In the latter group, the in-hospital mortality rate was 21.3%, and the mortality rate after discharge was 18.8%. One-year survival was significantly higher among the immunocompetent patients than among the HIV patients (p = 0.008) and the non-HIV-infected immunocompromised patients (p = 0.015), although there was no such difference between the two latter groups (p = 0.848). Among the non-HIV-infected immunocompromised patients, the only factor statistically associated with mortality was the need for mechanical ventilation. Among the patients over 60 years of age, fibrosis/atelectasis on chest X-rays and dyspnea were more common, whereas fever and consolidations were less common. Fever was also less common among the patients with neoplasms. The time from admission to the initiation of treatment was significant longer in patients over 60 years of age, as well as in those with diabetes and those with end-stage renal disease. Weight loss was least common in patients with diabetes and in those using corticosteroids.

Conclusions: The lower prevalence of classic symptoms, the occurrence of extrapulmonary tuberculosis, the delayed initiation of treatment, and the high mortality rate reflect the diagnostic and therapeutic challenges of tuberculosis in non-HIV-infected immunocompromised patients.

Download full-text PDF

Source
http://dx.doi.org/10.1590/s1806-37132010000400013DOI Listing

Publication Analysis

Top Keywords

non-hiv-infected immunocompromised
20
immunocompromised patients
20
patients
14
patients in-hospital
12
in-hospital diagnosis
12
mortality rate
12
diagnosis tuberculosis
8
factors mortality
8
extrapulmonary tuberculosis
8
patients years
8

Similar Publications

Article Synopsis
  • Pneumocystis jirovecii (PJ) is an opportunistic fungus that can cause serious lung infections, particularly in immunocompromised individuals, leading to significant morbidity and mortality.
  • While there are established prevention strategies for HIV-infected patients, there is limited research on how to manage PJ infections in non-HIV populations.
  • Deciding on prophylaxis for PJ involves evaluating the patient's clinical situation and risk factors, with no strong indicators available to reliably predict Pneumocystis pneumonia (PCP) occurrence; thus, decisions should be personalized.
View Article and Find Full Text PDF
Article Synopsis
  • Pneumocystis jirovecii infection primarily targets immunocompromised individuals, but a case is reported in a relatively healthy 46-year-old man with no history of such conditions.
  • The patient exhibited symptoms like dry cough and dyspnea, with unique imaging results showing a "crazy-paving" pattern, leading to a confirmed diagnosis through biopsy.
  • Despite having no immunosuppressive factors, malnutrition may have played a role in the infection, highlighting a potential risk for PJP in otherwise healthy individuals.
View Article and Find Full Text PDF

Monkeypox (mpox) is an orthopoxviral zoonotic disease with a similar but less severe clinical presentation as smallpox. However, immunocompromised patients such as solid organ transplant recipients are at higher risk of developing severe forms of the disease. Herein, we describe the case of a 43-year-old female kidney transplant recipient that manifested severe skin ulcers alongside nodular lung opacities and pleural effusion attributed directly to the monkeypox virus.

View Article and Find Full Text PDF

Background: Trimethoprim-sulfamethoxazole (TMP-SMX) is an effective treatment for Pneumocystis jirovecii pneumonia (PCP) in immunocompromised patients with and without HIV infection; however, a high incidence of adverse events has been observed. Low-dose TMP-SMX is a potentially effective treatment with fewer adverse events; however, evidence is limited.

Research Question: What is the efficacy and safety of low-dose TMP-SMX for non-HIV PCP compared with conventional-dose TMP-SMX after adjusting for patient background characteristics?

Study Design And Methods: In this multicenter retrospective cohort study, we included patients diagnosed with non-HIV PCP and treated with TMP-SMX between June 2006 and March 2021 at three institutions.

View Article and Find Full Text PDF

Background: The number of pneumocystis pneumonia (PCP) cases is increasing in immunocompromised patients without human immunodeficiency virus infection (HIV), causing serious morbidity with high mortality. Trimethoprim/sulfamethoxazole (TMP/SMZ) monotherapy has limited effectiveness in the treatment of PCP. Clinical data on whether initial caspofungin plus TMP/SMZ for this disease is superior to monotherapy in non-HIV-infected patients are limited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!